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Genetic association of miRNA-146a with systemic lupus
erythematosus in Europeans through decreased expression
of the gene
SE Lo¨fgren1, J Frostega˚rd2, L Truedsson3, BA Pons-Estel4, S D’Alfonso5, T Witte6, BR Lauwerys7, E Endreffy8, L Kova´cs9, C Vasconcelos10,
B Martins da Silva11, SV Kozyrev,12,15 and ME Alarco´n-Riquelme,13,14,15
A recent genome-wide association study revealed a variant (rs2431697) in an intergenic region, between the pituitary tumor-
transforming 1 (PTTG1) and microRNA (miR-146a) genes, associated with systemic lupus erythematosus (SLE) susceptibility.
Here, we analyzed with a case--control design this variant and other candidate polymorphisms in this region together with
expression analysis in order to clarify to which gene this association is related. The single-nucleotide polymorphisms (SNPs)
rs2431697, rs2910164 and rs2277920 were genotyped by TaqMan assays in 1324 SLE patients and 1453 healthy controls of
European ancestry. Genetic association was statistically analyzed using Unphased. Gene expression of PTTG1, the miRNAs miR-
3142 and primary and mature forms of miR-146a in peripheral blood mononuclear cells (PBMCs) were assessed by quantitative
real-time PCR. Of the three variants analyzed, only rs2431697 was genetically associated with SLE in Europeans. Gene
expression analysis revealed that this SNP was not associated with PTTG1 expression levels, but with the microRNA-146a, where
the risk allele correlates with lower expression of the miRNA. We replicated the genetic association of rs2341697 with SLE in a
case--control study in Europeans and demonstrated that the risk allele of this SNP correlates with a downregulation of the
miRNA 146a, potentially important in SLE etiology.
Genes and Immunity (2012) 13, 268--274; doi:10.1038/gene.2011.84; published online 5 January 2012
Keywords: autoimmunity; inﬂammation; microRNAs; miR146a; systemic lupus erythematosus
INTRODUCTION
The genome-wide association studies (GWAS) that have been
carried out in the last years have revealed a great number of
genetic variants predisposing to different complex diseases,
including systemic lupus erythematosus (SLE). SLE is a complex
autoimmune disease characterized by the production of auto-
antibodies, formation of deleterious immune complexes and
systemic inﬂammation in multiple organs. Aside from dysregula-
tion of adaptive immunity, many studies have shown the
association of innate immune responses with SLE pathogenesis,
such as the involvement of the complement system, activation of
Toll-like and Fcg receptor-mediated signaling.1 In addition, the
importance of the type I interferon (IFN) system for disease
development was shown.2 - 4 Many SLE patients have elevated
serum levels of IFN-a, a key regulator of innate immunity, and
increased expression of IFN-a-inducible genes in the white blood
cells, termed the ‘interferon signature’, which could be correlated
with both disease activity and severity, and has also been
observed in several other autoimmune diseases.2 - 4
In the majority of genetic studies, the associations target
regions that are far away from known genes and the biological
importance of such variants is rather unknown. In the case of SLE,
a recent GWAS revealed an association signal for a single-
nucleotide polymorphism (SNP) rs2431697 located in an inter-
genic region, between the pituitary tumor-transforming 1 (PTTG1)
and the microRNA-146a (miR-146a) genes.5 PTTG1 gene codes for
a protein called securin, primarily important in the regulation of
sister chromatid separation during cell division, and that has been
consistently related to several types of cancer.6 miR-146a, on the
other hand, is a microRNA (miRNA) recently described as an
important player in the regulation of innate and adaptive immune
system as well as in regulating tumor progression.7
miRNAs represent a recently discovered class of small, non-
coding RNAs, present in virtually all species. miRNAs have revealed
a new mechanism of gene expression regulation, playing a crucial
role in ‘ﬁne-tuning’ negative regulation in many physiological and
pathophysiological processes.8 - 11 A growing number of miRNAs
like miR-125b, miR-150, miR-155, miR-181a/b, miR-223, miR-101,
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miR-16 and miR-146a have been associated with regulation of
diverse immune functions including T-cell selection, B-cell
maturation and selection, and development of regulatory T cells
(Tregs), suggesting that the miRNA regulatory mechanism may be
central in immunological tolerance (reviewed in Pauley et al.11 and
Tsitsiou and Lindsay12).
miR-146a was ﬁrst described in 2006 by Taganov et al.13 in
human acute monocytic leukemia cell line, showing also its
upregulation in response to stimulation with lipopolysaccharides
and its role as a negative feedback regulator of the Toll-like
receptor signaling by targeting TRAF6 (tumor necrosis factor
receptor-associated factor 6) and IRAK-1 (interleukin-1 receptor-
associated kinase 1), suggesting for the ﬁrst time its important role
as a negative regulator of inﬂammation.
To date, neither the functional role of the SNP rs2431697 nor
the gene to which this association could be related to has been
investigated. In this study, we replicated a strong genetic
association of this variant with susceptibility to SLE in Europeans
and demonstrated a correlation of the risk allele of this SNP with
lower expression of the miR-146a, relevant in SLE pathology.
RESULTS
Association of the intergenic variant rs2431697 with SLE
We investigated the genetic association of three candidate SNPs
in the PTTG1-miR146a region (rs2431697, rs2277920 and
rs2910164) in an European multicenter collection from seven
European countries. Genotyping call rates were 495%, and there
was no evidence of deviation from Hardy--Weinberg Equilibrium
of any SNP (P40.6). By likelihood-based association analysis
(Unphased), there was no association of rs2910164 or rs2277920
(proxy for rs57095329) with SLE (Table 1). To note, the frequency
of the risk allele of rs2277920/rs57095329 found associated with
SLE in Chinese (frequency of 0.16--0.29) was very low in our
European cohort (B0.027), showing that this risk variant is barely
present in Europeans.14
rs2910164 is an interesting SNP since it has been shown to
affect the efﬁciency of the premature miR-146a processing, which
results in differential expression levels of the mature miRNA.15
However, no association was found for this SNP with susceptibility
to SLE in our European cohort, which is in concordance to the
recent study showing no association of this variant in Han Chinese
either.14
Our meta-analysis replicated, on the other hand, a robust
association of rs2431697 with SLE (P¼ 0.00028, odds ratio¼ 1.23
(1.10--1.38)) with the homozygosity for the risk allele having an
odds ratio of 1.49.
The linkage disequilibrium (LD) between those three poly-
morphisms was proven to be extremely low (Figures 1 and 2); and
thus, these variants can be considered as completely independent
markers in this region. Also, considering the whole PTTG1-miR146a
region in HapMap, rs2431697 was found to be rather independent
of any major LD block in this region (Figure 1).
Association of rs2431697 with miR146a expression
After conﬁrming the genetic association of rs2431697 with SLE
susceptibility in our cohort, we aimed to analyze if this SNP would
have an effect on expression levels on either PTTG1 or miR146a
genes. Since this polymorphism is located approximately in the
middle between the two genes (24.23 kb downstream of the
PTTG1 gene and 15.3 kb upstream of miR-146a exon 1), it was
unclear to which gene the association of this SNP was related to.
We ﬁrst attempted to investigate PTTG1 expression levels in
peripheral blood mononuclear cell (PBMC) samples with different
genotypes for rs2431697. PTTG1 expression proved to be very low
in these cells; however, no difference was seen between the
genotypes (Figure 3a). We next analyzed if the SNP was associated
with the expression levels of the mature form of miR-146a, and we
found a decrease ofB1.6-fold in the individuals’ homozygotes for
the risk allele (P¼ 0.008; Figure 3b). The expression levels of mat-
miR-146a are known to be dependent on the SNP rs2910164,
which we could corroborate (Figure 3c); however, since both
variants are not in LD with each other, this effect is rather
independent of rs2910164. To validate that rs2431697 exerts an
independent of rs2910164 effect, we analyzed the expression of
the full-length primary miR-146a transcript consisting of two
exons. We found that there was indeed a correlation of rs2431697
with a downregulation of primary miR-146a transcript ofB2.2-fold
(P¼ 0.009) in ‘risk’ homozygotes (Figures 3d and e).
Table 1. Genetic association of the variants in PTTG1-miRNA-146a region
Allelic association
Risk allele counts and frequencies
Case Control Ca-Freq Co-Freq P-value OR (95% CI)
rs2431697 1370 1586 0.620 0.569 0.00028 1.23 (1.10 --1.38)
rs2277920 66 72 0.029 0.026 0.360 1.17 (0.84 --1.64)
rs2910164 550 687 0.248 0.240 0.541 1.04 (0.92 --1.18)
Genotypic association
rs2431697 P¼ 0.0006
C/C 157 240 0.142 0.172 0.040 1
C/T 524 718 0.475 0.516 0.041 1.12 (0.89 --1.41)
T/T 423 434 0.383 0.312 0.00019 1.49 (1.17 --1.90)
rs2277920 P¼ 0.166
A/A 1044 1338 0.942 0.949 0.461 1
G/A 62 72 0.056 0.051 0.587 1.10 (0.78 --1.57)
G/G 2 0 0.002 0 0.111 8.2 109a
rs2910164 P¼ 0.553
G/G 623 819 0.562 0.574 0.553 1
C/G 422 531 0.381 0.372 0.655 1.05 (0.89 --1.23)
C/C 64 78 0.058 0.055 0.737 1.08 (0.76 --1.53)
Abbreviations: CI, confidence interval; miRNA, microRNA; OR, odds ratio; PTTG1, pituitary tumor-transforming 1.
Risk alleles: rs2431697-T, rs2277920-G and rs2910164-C.
aSince the frequency of this genotype is very rare and present only in the case group the OR for this genotype was disproportionally high.
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We further analyzed the expression of the miR-146a transcripts
in lymphoblastoid cell lines (LCLs) with different genotypes. In
these cells, the expression of PTTG1 and mature miR-146a was not
signiﬁcantly different between the rs2431697 genotypes
(P¼ 0.663 and P¼ 0.057, respectively), although a trend of miR-
146a toward decreased levels was seen in the cells homozygous
for the risk allele (Figure 3f). However, when investigating the
primary transcript we could detect a signiﬁcant difference in
expression between genotypes (P¼ 0.047; Figure 3g).
In the latest version of the human genome assembly (hg19)
available, a new microRNA (miR-3142) was annotated in the
intronic region of the miR-146a gene (Figure 2). This miRNA was
identiﬁed by deep sequencing in a pigment cell and melanoma
library16 and was included in the miRBase (www.mirbase.org, v.17,
Figure 1. LD structure of the SNPs in the PTTG1-miR-146a region generated from HapMap (release 28) with Haploview version 4.2. LD blocks
(r2) were defined using the solid spine method.
50kb
mir-146amir-3142
Chr5 (q33.3)
PTTG1 pri-miR-146a
rs2431697 (T/C) rs2277920 (A/G) rs2910164 (G/C)
rs57095329 (A/G)
r2=1*
Figure 2. Schematic representation of the PTTG1-miR146a genomic region and the position of the SNPs analyzed. Exons are shown as black
bars and dotted line represents the intergenic region. The location of the two mature miRNA annotated in this region, miR-3142 and miR-146a,
is indicated in the pri-miR-146a transcript. The positions of the four SNPs included in this study are indicated, together with the LD plot
showing the linkage (r2) between them (generated with Haploview from our genotyping data, except for the LD between rs2277920 and
rs57095329 (*) that was extracted from 1000 genomes pilots for Utah residents with ancestry from northern and western Europe (CEU) and
Han Chinese in Beijing, China (CHB)þ Japanese in Tokyo, Japan (JPT).
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April 2011). Since we observed signiﬁcantly altered levels of miR-
146a primary transcript, we also wondered if it could correlate
with miR-3142 levels as well. Thus, we used a TaqMan assay for the
mature form of this miRNA to test the expression in both PBMCs
and LCLs. However, we could not detect any expression of miR-
3142 in our samples, although the control snRNA (RNU66) was
expressed at high levels (data not shown).
DISCUSSION
To date, the importance of miRNAs in regulation of many immune
processes has been widely shown and includes examples of
regulation of granulopoiesis, T- and B-cell development and
maturation, antigen presentation, Toll-like receptor signaling and
cytokine production, immunoglobulin class-switch recombination
in B cells, and T-cell receptor signaling.17 The crucial role of
miRNAs in regulating in a ‘ﬁne-tuning’ manner the immune
response can be enlighten by the need of the immune system
to avoid uncontrolled and overreacted immune responses,
which potentially leads to substantial self-damage. In fact, the
importance of this regulation is demonstrated by the severe
impairment in the development and/or function of immune cells
when miRNA expression is experimentally altered or by the fact
that they can be correlated with many different immune-related
diseases.11,18 Thus, the ablation of miR-146a, the subject of the
present study, in Treg cells in a knockout mouse model led to the
development of autoimmune disease with severe break-down of
immunological tolerance, leading to fatal IFN-g-dependent
immune-mediated lesions in many different organs.7
Changes in miR-146a expression have been observed in a
number of human diseases, such as inﬂammatory and auto-
immune diseases, viral infections, sepsis, multiorgan failure, and
cancer (reviewed in Li et al.19). In the case of autoimmune
diseases, numerous studies have shown that miR-146a is
upregulated in synovial tissue and PBMCs of rheumatoid arthritis
(RA) patients18,20,21 as well as in skin lesions of psoriasis patients.22
On the other hand, miR-146a expression levels were signiﬁcantly
decreased in PBMCs from patients with type 2 diabetes.23 The
controversial observations on the expression levels of miR-146a in
various autoimmune diseases may be attributed to the differences
in the pathogenic pathways important for different diseases as
well as the stage at which the samples have been taken during
disease development.
Tang et al.24 showed a threefold downregulation of miR-146a,
which negatively correlated with disease activity and IFN scores, in
SLE patients. The authors also reported that beside TRAF6 and
IRAK1, miR-146 also regulates the levels of the signal transducer
and activator of transcription 1, and IFN regulatory factor 5, all of
which are key players in the type I IFN pathway. The over-
expression of miR-146a in normal PBMC greatly reduced the
induction of type I IFN, while on the other hand the inhibition of
endogenous miR-146a increased its production in response to
activation of Toll-like receptor-7. Thus, decreased expression of
miR-146a in PBMC may contribute to the enhanced type I IFN
production observed in SLE.
The analysis of serum miR-146a also showed the reduced levels
in the serum supernatants from SLE patients, and that the levels
could be correlated with renal function, proteinuria and disease
activity in patients.25
Polymorphisms affecting miRNA expression, maturation or
mRNA recognition may represent an important risk determinant
in disease susceptibility. In miR-146a, a variant was described in
the passenger strand of the pre-miRNA (rs2910164) that was
associated with susceptibility to papillary thyroid cancer and
shown to affect miR-146a processing. This led to reduced levels of
pre-miR-146a as well as mat-miR-146a and eventually to an
increased expression of the target genes, including TRAF6 and
IRAK1.15 This SNP has been further controversially associated with
some forms of cancer, such as cervical cancer,26 but failed to
correlate with others27 - 29 as well as atrial ﬁbrillation.26 Interest-
ingly, it was not associated with psoriatic arthritis,30 neither with
RA nor with SLE in Asians,31,32 but to our knowledge this is the ﬁrst
study to investigate the role of this variant in SLE susceptibility in
Europeans. As in other related diseases, this variant, despite its
interesting functional consequences, is apparently not relevant to
SLE susceptibility.
A very recent study also described a variant, rs57095329, in the
promoter region of miR-146a primary transcript associated with
SLE in Chinese and with downregulation of miR-146a expression
through reduced binding afﬁnity of the transcription factor
Ets-1.14 According to HapMap data, the frequency of the risk
allele identiﬁed in this study is very low in the (Utah residents with
ancestry from northern and western Europe (CEU)) population
(0.017), while in Asian and Africans this variant is considerably
more frequent (0.20 --0.24). In our study, we included an SNP
rs2277920 located 257 bp downstream of exon 1 donor splice site
of the miR-146a primary transcript that could be of signiﬁcance to
splicing of the full-length transcript. This variant is in complete LD
with rs57095329 found associated with SLE in Chinese and is
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Figure 3. PTTG1 and miR-146a gene expression analysis in PBMCs
(a --e) and LCLs (f, g) from healthy donors, stratified by genotypes.
No association was seen with PTTG1 expression (a) neither for
rs2910164 with the primary transcript of miR-146a (e). As for
corroboration of previous findings, rs2910164 correlated with
miR-146a expression levels (c). Both mature and primary forms
of miR146a were significantly downregulated in individuals’
homozygotes for the risk allele of rs2431697 (b, d). miR-146a
expression analysis in LCLs also showed a trend of downregulation
of mat-miR146a (f ) and statistically lower levels of pri-miR-146a (g) in
cells from individuals homozygotes for the rs2431697 risk allele.
Values correspond to means ±s.e.m. error bars. Expression levels
were normalized to 18S rRNA.
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therefore a proxy of this polymorphism. We determined that
rs2277920 is not signiﬁcant in conferring susceptibility to SLE in
Europeans and by that also highlight the ethnical difference in the
genetic background of SLE susceptibility and the importance of
genetic studies in distinct populations.
The upstream SNP rs2431697, on the other hand, was ﬁrst
identiﬁed as a susceptibility variant for SLE in a GWAS in
Europeans5 and has later also been genetically associated with
psoriasis in a Chinese GWAS,33 but not with RA in an European
case--control study.34 Considering the opposite expression levels
of miR-146a found in SLE and RA patients,19,24 it seems coherent
the fact that this SNP may not be genetically associated with RA.
The same study that identiﬁed the functional SNP rs57095329
also detected a strong genetic association of rs2431697 as an
independent associated locus,14 suggesting that this variant is
most likely a common risk variant among distinct populations.
The molecular mechanism of how the T allele of rs2431697
leads to the downregulation of miR-146a requires a more detailed
analysis. A bioinformatic examination of the region with rs2431697
was carried out in an attempt to elucidate its potential regulatory
role on miR-146a expression. The SNP is located in a region with
high regulatory potential---it overlaps with the DNase I hypersensi-
tivity cluster and H3K4me3 trimethylation marks as well as with
ChIP-seq signals for Pol II and transcription factors NF-kB and PAX5
(Encode transcription factor ChIP-seq and Encode digital DNase I
hypersensitivity clusters databases, available at UCSC genome
browser http://www.genome.ucsc.edu/cgi-bin/hgGateway). Thus,
either this variant itself or some others in LD with it may have a
role in the regulation of miR-146a transcription. Further analysis by
targeted resequencing or ﬁne mapping of this region in European
SLE patients and controls may possibly reveal the genetic
architecture of the locus and help identify causative variant. It is
important to note, that contrary to the results presented here, in a
study by Luo et al.14 this variant was not found associated with
expression of mir146a, but rather its expression was dependent on
the alleles of rs57095329. Given the extremely low frequency of
the minor allele of the latter SNP in Europeans and lack of LD
between rs2431697 and rs57095329, we ﬁnd it difﬁcult to explain
the differential expression of mir146a in Europeans by rs57095329
only. It might be that the associated region shared between the
Europeans and Asians and represented by the SNP rs2431697 has
a bigger role in miR-146a transcriptional regulation; and further
the gene expression is modulated by ethnic-speciﬁc variants. As
we showed here, the regulation takes place at the level of
transcription rather than maturation of miRNA, since it affects the
levels of the full-length primary RNA transcript.
It will be of great interest to further investigate the effect of this
variant on expression of miR-146a in speciﬁc cell populations of
leukocytes. Cell type-speciﬁc regulatory mechanisms may not only
affect the expression of the miRNA but also lead to the more
dramatic changes in the pattern of genes regulated by miR-146a.
We also do not exclude the possibility that expression of the
recently discovered miRNA miR-3142 located in intron 1 of the
miR-146a gene could be dependent on the SNP rs2431697 as well.
Although, according to our data it is not expressed in peripheral
mononuclear blood cells, it still may be expressed in some other
tissues.
In summary, we found that rs2431697 is associated with SLE in
Europeans and that the T allele of this SNP correlates with lower
expression of the miR-146a gene which could lead to enhanced
function of the target genes involved in type I IFN pathway
important for SLE.
MATERIALS AND METHODS
Study subjects
The study group comprised a total of 1324 SLE patients and 1453 ethnicity-
matched healthy controls, including 62 patients and 97 controls from
Argentina, 63 patients and 70 controls from Belgium, 391 patients and 190
controls from Germany, 75 patients and 57 controls from Hungary, 357
patients and 382 controls from Italy, 175 patients and 176 controls from
Portugal and 201 patients and 481 controls from Sweden. All SLE patients
fulﬁlled the American College of Rheumatology classiﬁcation criteria for
SLE and all individuals were tested for European ethnicity by principal
component analysis.
SNP selection and genotyping
Three SNPs in the PTTG1-miR146a region, rs2431697, rs2277920 and
rs2910164 were chosen to be genotyped in a large case -- control European
cohort. The SNP rs2431697 is situated in the intergenic region between the
PTTG1 and miR146a genes and has previously been associated with SLE in
a GWAS study in Europeans.5 The second intronic SNP rs2277920 is located
257 bp downstream of exon 1 donor splice site of the miR-146a primary
transcript and was chosen for genotyping because of its location in the
region with the potential to affect splicing of exon 1. Given that the SNP
rs2277920 is a proxy (r2¼ 1 in 1000 genomes pilots for Utah residents with
ancestry from northern and western Europe (CEU) and Han Chinese in
Beijing, China (CHB)þ Japanese in Tokyo, Japan (JPT)) of rs57095329, the
SNP recently found associated with SLE in Chinese,14 the results obtained
for rs2277920 in our European cohort could be attributed to rs57095329.
The third SNP rs2910164 is located in the miR-146a passenger strand and
has been shown to inﬂuence the expression levels of the mature miR-
146a,15 but its association with SLE or any other autoimmune diseases in
Europeans had not been investigated yet. All SNPs were genotyped by
TaqMan allelic discrimination assays (Applied Biosystems, Foster City, CA,
USA). All genotyping was performed at Uppsala University using ABI PRISM
7900HT Fast Real-Time PCR System (Applied Biosystems).
Statistical analysis of genetic association
Allelic and genotypic association of the polymorphisms with SLE was
evaluated using Unphased version 3.1.5 (University of Cambridge, Cam-
bridge, UK), including the country of origin as a stratiﬁcation variable.
Pairwise LD analysis of the PTTG1-miR-146a region and Hardy - Weinberg
equilibrium tests were performed with Haploview version 4.2 (Broad
Institute of Harvard and MIT, Cambridge, MA, USA).
GraphPad Prism software (www.graphpad.com) was used for statistical
analysis and calculation of mean±s.e.m. values of the gene expression
data. Comparisons were performed using two-tailed unpaired t-test.
Gene expression analysis
For the analysis of expression levels of PTTG1, miR-146a and miR-3142,
total RNA was extracted with TRIzol reagent (Invitrogen, Life Technologies,
Carlsbad, CA, USA) from 87 PBMC samples collected from healthy Swedish
individuals at Uppsala University Hospital. In addition, we analyzed
expression of these genes in 44 LCLs with different genotypes. cDNA
was synthesized from 2 mg of total RNA at 42 1C for 80min followed by
heat inactivation at 95 1C for 5min. The reaction contained 1.25mM
random hexamers, MuLV transcriptase, RNase inhibitor and buffer
supplemented with 5mM MgCl2 and 1mM dNTPs. Quantitative PCR for
PTTG1, the primary transcript of miR-146a (pri-miR-146a) and 18S rRNA
were performed using 15 ng cDNA, PCR buffer, 1.5mM MgCl2, 200 mM
dNTPs, 0.5 U Platinum Taq polymerase (Invitrogen), 0.25 mM of each primer
and SYBR Green (Molecular Probes, Eugene, OR, USA) for ampliﬁcation
detection. The PCR conditions were as follows: denaturation at 95 1C for
5min, followed by 40 cycles of 15 s at 95 1C, 15 s at 60 1C, 30 s at 72 1C and
ﬁnal extension at 72 1C for 3min. Expression of PTTG1 and pri-miR-146a
was normalized by that of 18S rRNA. The primers used were as follows:
PTTG1 forward: GCGGCTGTTAAGACCTGCAATAATCCA, PTTG1 reverse: GTTC
GATGCCCCACCAGCCT; pri-miR-146a forward: TTAGGAGCTCGCTGGCTGGG
ACA, pri-miR-146a reverse: CAGGATCTACTCTCTCCAGGTCCTCA. Mature
miRNAs (miR146a, miR3142) and the snRNA-control RNU66 were reverse
transcribed and quantiﬁed with TaqMan microRNA expression assays
(ABI assay IDs 000468, 244120-mat and 001002, respectively), according to
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the manufacturer’s instructions. Brieﬂy, cDNA was produced from 10ng of
total RNA with the commercial miRNA-speciﬁc stem-loop primers.
Quantitative PCR was performed using the speciﬁc microRNA TaqMan
assay.
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